Safety profile of treatments administered in COVID 19 infection in pregnant women

SARS-CoV-2 infection has unexpectedly arrived in our society. In pregnant women, the situation has been similar to general population. Some drugs have been used empirically, and obstetricians have to consider whether the same treatments used in the general population were valid for pregnant women wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Sánchez, N., De la Calle Fernández-Miranda, M., Bartha, J.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier España, S.L.U. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906532/
https://www.ncbi.nlm.nih.gov/pubmed/33654337
http://dx.doi.org/10.1016/j.gine.2021.01.004
Descripción
Sumario:SARS-CoV-2 infection has unexpectedly arrived in our society. In pregnant women, the situation has been similar to general population. Some drugs have been used empirically, and obstetricians have to consider whether the same treatments used in the general population were valid for pregnant women with severe disease, according to their safety profile for both the mother and the fetus. There has been a wide experience with the use of hydroxychloroquine and lopinavir/ritonavir in pregnant women. Tocilizumab and interferon beta could be used if benefits exceed risks. There is no experience using remdesivir in pregnancy.

Ejemplares similares